AI virtual trials match real trial results for GLP-1 vs insulin in type 2 diabetes
Key Takeaway:
AI models can recreate trial results, but need more validation before use in treatment decisions.
Study at a Glance
What was studied
AI model using data from 5,476 people to recreate a diabetes drug trial.
Study Type
non-randomized clinical trial (non-RCT or NRCT)
duration
Medium-Term (3–12 mo)
Intervention
GLP-1 receptor agonists, Basal insulin
Outcomes
HbA1c, Body weight, Systolic blood pressure
Funding
Non-Industry Sponsored
Save this study and add notes to your research library.
Main Effects
HbA1c → ↓ (GLP-1 better than insulin)
Weight (BMI) → ↓ (GLP-1 better than insulin)
Blood pressure → ↓ (GLP-1 better than insulin)
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Basal insulin (Medications) |  Body weight (Weight & Anthropometrics) | Increase | Mixed |
Basal insulin (Medications) |  HbA1c (Glycemic Control) | Decrease | Mixed |
Basal insulin (Medications) |  Systolic blood pressure (Metabolic Health) | Decrease | Limited |
GLP-1 receptor agonists (Medications) | Body weight (Weight & Anthropometrics) | Decrease | Strong |
GLP-1 receptor agonists (Medications) | HbA1c (Glycemic Control) | Decrease | Strong |
GLP-1 receptor agonists (Medications) | Systolic blood pressure (Metabolic Health) | Decrease | Strong |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- AI models can recreate results from real diabetes trials, correctly showing GLP-1 drugs work better than insulin for blood sugar, weight, and blood pressure.
- Treatment benefits may vary by individual, with GLP-1 not always the best choice for everyone.
- This AI method needs more testing before it can be used widely for treatment decisions.
Who this applies to
People with type 2 diabetes on metformin and sulfonylurea considering GLP-1 or insulin treatment; healthcare providers choosing between treatment options; researchers testing new AI methods for drug evaluation.
Keep in Mind
This tests an AI method, not actual treatments, so it doesn't provide new clinical evidence.
Between the Lines
- Tested drug classes, not specific medications
- Virtual patients showed less variation than real people
- Only validated against one trial
- Excluded records with missing data
Journal Reference
MacLellan CR, Petkov H, McKeag C, et al. Emulating real-world GLP-1 efficacy in type 2 diabetes through causal learning and virtual patients. PLOS Digit Health. 2025;4(7):e0000927. doi:10.1371/journal.pdig.0000927
Connected Evidence
Discover how this study fits into the broader diabetes evidence landscape.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and Glycemic Control.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention–outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
Measures Body Weight as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
Glycemic Control Evidence Hub
All studies measuring Glycemic Control
Measures Glycemic Control as a key outcome.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on GLP-1 receptor agonists and Body weight
1 results
All studies on GLP-1 receptor agonists and HbA1c
1 results
All studies on GLP-1 receptor agonists
1 results
All studies measuring Body weight
1 results
All studies measuring HbA1c
1 results
Questions this evidence helps answer
Key clinical and research questions this study contributes to.
Does glp-1 receptor agonists improve Body weight?
Based on connected evidence for GLP-1 receptor agonists and Body weight.
Does glp-1 receptor agonists affect HbA1c in people with diabetes?
Exploring evidence on GLP-1 receptor agonists and HbA1c outcomes.
What does the evidence say about glp-1 receptor agonists and Systolic blood pressure?
Review of studies examining GLP-1 receptor agonists and Systolic blood pressure.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.